Aim:We report the availability and tolerance of Paclitaxel-Carboplatin-Bevacizumab for patients with stage 4B and recurrent cervical cancer. Methods:We analyzed twenty-eight patients with stage 4B and recurrent cervical cancer who were treated by Paclitaxel-Carboplatin-Bevacizumab between May 2016 and April 2018 at our hospital. Treatment outcome, adverse event, progression free interval and overall survival were analyzed retrospectively. Results:The median follow-up period was 9 months (range = 1-19 months) and the median age was 49.5 years old (range = 28-74 years old). Seventeen patients (60.7) were recurrence, and eleven patients (39.3%) were stage 4B (FIGO2008) cervical cancer. The majority of pathology was squamous cell carcinoma (twenty patients, 71.4%), thirteen patients (46.4%) had a history of prior radiotherapy for their pelvis, and eleven patients (39.3%) had a history of prior platinum chemotherapy. Two patients (7.1%) had only pelvic organ lesion, twelve patients (42.9%) had only distant organ metastasis, and fourteen patients (50.0%) had both distant organ metastasis and pelvic organ lesion. The median cycle of Paclitaxel-Carboplatin was 6 (range = 1-17), and the median cycle of Bevacizumab was 5.5 (range = 1-16). Three patients (10.7%) were interrupted to administer Bevacizumab because of the adverse event. One patient (3.6%) had a perforation of sigmoid colon after the administration of Bevacizumab. The median overall survival was 9 months (range = 1-20 months), and the median progression free survival was 10 months (range = 0-18 months). Disease control rate was 85.7% (twenty-four of twenty-eight cases). Three patients (10.7%) were no evidence of disease, eighteen patients (64.3%) were alive with disease and seven patients (25.0%) were died of disease. Conclusion:It is suggested that Paclitaxel-Carboplatin-Bevacizumab is available for patients with stage 4B and recurrent cervical cancer, but severe adverse event can be occurred.